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740 The Journal of Thoracic and CardioObjective: The aim of this study was to evaluate the expression of dysadherin and
E-cadherin and to investigate their clinical significance as prognostic factors in
non–small cell lung cancer.
Methods: Non–small cell lung cancer specimens were obtained from 131 patients
undergoing clinically indicated operations at the Department of General and Car-
diothoracic Surgery, Kanazawa University Hospital, between 1995 and 1997. All
patients had undergone curative resection of the primary tumor, including system-
atic lymph node dissection. The avidin-biotin-peroxidase complex method was used
for immunostaining of dysadherin and E-cadherin.
Results: Among the 131 lung cancer specimens, 46 (35.1%) tumors were positively
stained with dysadherin. Preserved membranous E-cadherin staining was present in
45.8% (60/131) of cases. In this analysis dysadherin expression was not correlated
with E-cadherin expression (P  .1333), but a significant association was observed
between dysadherin expression and survival time. The overall survival of patients
with dysadherin-positive tumors was significantly worse than that of those with
dysadherin-negative tumors (P  .0059). Patients with reduced E-cadherin immu-
nopositivity survived significantly shorter than those with preserved E-cadherin
immunopositivity (P  .0406). The overall survival of patients with positive
dysadherin and reduced E-cadherin expression was significantly worse than that of
patients with negative dysadherin and preserved E-cadherin expression (P .0002).
Multivariate analysis revealed the independent prognostic value of dysadherin
positivity, reduced E-cadherin expression, and lymph node metastasis on overall
survival.
Conclusions: Dysadherin expression is an independent prognostic factor of survival
in patients with non–small cell lung cancer, and combined immunohistochemical
analysis of dysadherin and E-cadherin expression might provide further prognostic
information.
Cell-cell adhesiveness determines the polarity of cells and is generally re-duced in human cancers. The cadherins are members of a large family oftransmembrane glycoproteins that mediate calcium-dependent, homophilic
cell-cell adhesion and play an important role in the maintenance of normal tissue
architecture. A tumor-suppressor gene product, E-cadherin, and its undercoat pro-
teins, catenins, which connect cadherins to actin filaments, are located at lateral
borders concentrating on adherens junctions of epithelial cells and establish firm
cell-cell adhesion. Hirata and associates1 reported that decreased E-cadherin ex-
pression showed a correlation with lymph node metastasis in resected non–small
cell lung cancer (NSCLC) and with the prognosis of patients with stage IIIA disease.
Recently, Ino and colleagues2 identified a novel cancer-associated cell membrane
glycoprotein, dysadherin, composed of 178 amino acids. The transfection of this
vascular Surgery ● September 2005
Tamura et al General Thoracic Surgery
G
TSmolecule causes E-cadherin downregulation and disturbs
homotypic cell adhesion in the human hepatocellular
carcinoma cell line PLC/PRE/5. Recent studies have
demonstrated that the increased expression of dysadherin
is correlated with decreased survival in patients with
colorectal cancer,3 thyroid cancer,4 and pancreatic ductal
carcinoma.5
In this study we examined for the first time the correla-
tion of dysadherin expression and clinicopathologic findings
and compared dysadherin expression and E-cadherin ex-
pression in patients with NSCLC.
Patients and Methods
Patients
NSCLC specimens were obtained from 131 patients (97 male and
34 female patients) undergoing clinically indicated operations at
the Department of General and Cardiothoracic Surgery, Kanazawa
University Hospital, between 1995 and 1997. All patients had
undergone curative resection of the primary tumor, including sys-
tematic lymph node dissection. Their ages ranged from 47 to 89
years (mean  standard deviation [SD], 66.1  9.2 years). The
sample selection was restricted to consecutive cases diagnosed as
stage I, II, and IIIA. None of the patients received chemotherapy
or radiation therapy preoperatively. Complete follow-up data were
obtained for at least 60 months, and the mean observation period
Figure 1. A and C, Immunohistochemical staining o
magnification: A, 100; C, 400.) Cell membranes are
tumor cells in which dysadherin was strongly express
staining of E-cadherin in the primary squamous cell cwas 67.2  29.1 months (range, 8-98 months).
The Journal of ThoraciMethods
Immunohistochemistry. The avidin-biotin-peroxidase complex
method was used for immunostaining of dysadherin and E-
cadherin, as described previously. In brief, a formalin-fixed and
paraffin-embedded block was obtained for each case. Five-
micrometer sections were mounted on poly-L-lysine–coated glass
slides and dried. After deparaffinization with xylene and rehydra-
tion with a series of decreased alcohol concentrations, antigen
retrieval was performed by placing microwave slides in citrate
buffer for 15 minutes. Endogenous peroxidase activity was
blocked in 0.3% hydrogen peroxidase in phosphate-buffered saline
(PBS; pH 7.2) for 15 minutes. After rehydration and washing in
PBS, sections were incubated with 10% normal goat serum
(DAKO) for 10 minutes at room temperature to block nonspecific
binding of the second antibody. Then sections were incubated with
anti-dysadherin antibody (1:500 dilution, Abcam) or anti-E-cadherin
antibody (1:200 dilution, Takara) at 4°C. The sections were
washed with PBS and incubated with biotinylated anti-goat im-
munoglobulin (Vectastain ABC Kit, Vector) for 20 minutes at
room temperature and washed again in PBS and reacted with
streptoavidin-biotin system (DAKO) for 20 minutes at room tem-
perature. Immune conjugate was visualized with PBS containing
both 0.02% (wt/vol) 3,3-diaminobenzidine tetrahydrochloride and
0.03% (wt/vol) hydrogen peroxide. All sections were counter-
stained with Meyer hematoxylin. Negative controls were prepared
by substituting PBS or Tris-buffered saline for the primary
sadherin in the primary adenocarcinoma. (Original
gly stained. B, E-cadherin expression was reduced in
riginal magnification 100.) D, Immunohistochemical
oma. (Original magnification 200.)f dy
stron
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arcinantibody.
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sections were analyzed in a blinded fashion without knowledge of
the patient’s clinical information. We assessed dysadherin expres-
sion as the percentage of positively stained tumor cells related to
total tumor cells. Expression of E-cadherin was considered posi-
tive if tumor cells were stained as strongly as normal epithelial
cells adjacent to the tumor, whereas those that stained weaker than
normal epithelial cells were considered negative. We also assessed
E-cadherin expression as the percentage of positively stained tu-
mor cells related to total tumor cells.
Statistical Analysis
All results were analyzed with a statistical analysis software
package (SPSS, Inc). The relation of clinicopathologic charac-
teristics to the number of immunopositive tumor cells was
analyzed by using the 2 test and analysis of variance where
appropriate. Dysadherin, E-cadherin, tumor differentiation, his-
tology, age, and sex were included in the assessment of prog-
nostic factors. Cancer-specific survival was defined as the time
between the operation and the last follow-up or cancer-related
death. Overall survival curves were determined by using the
Kaplan-Meier method and were analyzed with the log-rank test.
The Cox proportional hazard model was applied for univariate
TABLE 2. Correlation of E-cadherin and dysadherin expression
Dysadherin expression
E-cadherin expression >50% <50%
Preserved 16 44
Reduced 30 41
TABLE 1. Correlation between expression of E-cadherin an
with non–small cell lung cancer
Variables n
E-cadherin expres
Preserved
Total 131 60 (46)
Age (y)
65 48 26 (54)
65 83 34 (41)
Sex
Male 97 41 (42)
Female 34 19 (56)
Pathologic stage
I 74 38 (51)
II 20 6 (30)
III 37 16 (43)
Histology
Adenocarcinoma 81 35 (43)
Squamous cell carcinoma 50 25 (50)
Differentiation
Well 46 21 (46)
Moderate 52 26 (50)
Poor 33 13 (39)P  .1333.
742 The Journal of Thoracic and Cardiovascular Surgery ● Septand multivariate analysis to confirm the prognostic effect of the
factors on survival.
Results
Expression of Dysadherin
Dysadherin expression was present at the cell membrane
of cancer cells (Figure 1, A and C ). The possible associ-
ation with dysadherin was examined by using a standard-
ized scale of 0 to 4 (0, none; 1, 1% to 25%; 2, 26%
to 50%; 3, 51% to 75%; 4, 76% to 100% of cells).
The percentage of tumor cells that stained positively for
dysadherin was 46.4%  18.1% (mean  SD). Therefore
we set the cut-off value for dysadherin immunopositivity
at 50%. Among the 131 lung cancer specimens, there
were 46 (35.1%) tumors positively stained with dysad-
herin. Immunoreactivity for dysadherin was observed at
the cell-cell boundaries of cancer cells and heteroge-
neously in tumor nests. Analyses of the associations
between dysadherin and E-cadherin expression and clin-
icopathologic data are summarized in Table 1. Increased
dysadherin expression was correlated with the tumor
stage, although it was not statistically significant (P 
.0872). There was no significant association between
the dysadherin expression and age, sex, or tumor
differentiation.
Expression of E-cadherin
Expression of E-cadherin was also observed at the cell-cell
boundaries (Figure 1, C). The possible association with
sadherin and clinicopathologic characteristics in patients
(No. of patients [%]) Dysadherin expression (no. of patients [%])
ced P value <50% >50% P value
54) 85 (65) 46 (35)
46) 30 (62) 18 (38)
59) .2727 55 (66) 28 (34) .6642
58) 62 (64) 35 (36)
44) .1708 23 (68) 11 (32) .6983
49) 54 (73) 20 (27)
70) .2124 11 (55) 9 (45) .0872
57) 20 (54) 17 (46)
57) 49 (60) 32 (40)
50) .8846 36 (72) 14 (28) .0442
54) 33 (72) 13 (28)
50) .6098 32 (62) 20 (38) .3041
61) 20 (61) 13 (39)d dy
sion
Redu
71 (
22 (
49 (
56 (
15 (
36 (
14 (
21 (
46 (
25 (
25 (
26 (E-cadherin was examined by using a standardized scale of 0 to
ember 2005
Tamura et al General Thoracic Surgery
G
TS4 (0, none; 1, 1% to 25%; 2, 26% to 50%; 3, 51% to
75%; 4, 76% to 100% of cells). The percentage of tumor
cells that stained positively for E-cadherin was 72.2% 
16.8% (mean SD). Therefore, we set the cut-off value for
E-cadherin immunopositivity at 75%. Preserved membra-
nous E-cadherin staining was present in 45.8% (60/131) of
cases. There was no significant correlation between the
reduced expression of E-cadherin and age, sex, staging,
histology, or differentiation (Table 1). In this analysis dys-
adherin expression was not correlated with E-cadherin ex-
pression (P  .1333, Table 2).
Prognostic Value of Dysadherin and E-cadherin
Expression
A significant association was observed between dysadherin
expression and survival time. The overall survival of pa-
tients with dysadherin- positive tumors was significantly
worse than that of those with dysadherin-negative tumors
(P  .0059). The 5-year survival rates of the dysadherin-
positive group and the dysadherin-negative group were
27.5% and 53.6%, respectively (Figure 2, A). Patients with
reduced E-cadherin immunopositivity survived significantly
shorter than those with preserved E-cadherin immunoposi-
tivity (P  .0406; Figure 2, B). Overall survival of patients
with positive dysadherin and reduced E-cadherin expression
was significantly worse than that of patients with negative
dysadherin and preserved E-cadherin expression (P 
.0002; Figure 3, A). The 5-year survivals of the former and
the latter group were 56.0% and 14.3%, respectively. Sim-
ilarly, in patients with pathologic stage I disease, worse
prognosis could be found in patients with positive dysad-
herin and reduced E-cadherin expression than in patients
with negative dysadherin and preserved E-cadherin expres-
sion (73.3% vs 23.1%, P  .0088; Figure 3, B).
Multivariate analysis revealed the independent prognos-
Figure 2. Kaplan-Meier survival curves for dysadherin (
.0406, respectively.tic value of dysadherin positivity, reduced E-cadherin ex-
The Journal of Thoracipression, and lymph node metastasis on overall survival
(Table 3).
Discussion
Cell-cell adhesion appears to be a vital process in tumor cell
invasion and metastasis. In various cancerous tissues a
reduced expression of E-cadherin has frequently been ob-
served in cancer progression.6-12 Ino and colleagues2 re-
ported previously that dysadherin, a cancer-associated cell
membrane glycoprotein, has an anti–cell-cell adhesion
function and inactivate E-cadherin function in a posttran-
scriptional manner and plays an important role in tumor
progression and metastasis. In human subjects it was re-
ported that dysadherin expression was associated with a
high incidence of recurrence3 and decreased survival in
certain types of cancers.3-5 To our knowledge, this is the
first report to clarify the relationship among dysadherin
expression, clinicopathologic features, and survival in pa-
tients with NSCLC.
In this immunohistochemical study patients with increased
dysadherin expression had a tendency to show reduced E-
cadherin expression in NSCLC, but a statistically significant
difference could not be obtained. Sixteen (34.8%) of 46 pa-
tients with increased dysadherin expression had preserved
E-cadherin expression. Sato and coworkers4 indicated a
significant negative correlation between dysadherin expres-
sion and E-cadherin expression in 92 thyroid carcinoma
specimens. In thyroid cancer it appears that transcriptional
or posttranscriptional mechanisms, rather than structural
abnormalities of the E-cadherin gene, are responsible for the
downregulation of E-cadherin expression. Overexpression
of dysadherin was shown to downregulate E-cadherin post-
transcriptionally in liver cancer cells,2 although the molec-
ular mechanisms underlying this process are not clear. Shi-
d E-cadherin (B). Log-rank test for trend: P .0059 andA) anmamura and associates5 insisted that this discrepancy exists
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in the human pancreas mask the dysadherin function in the
downregulation of E-cadherin. We could find no correlation
between the cell type, differentiation, and the result of
immunohistochemical staining. This result suggests that a
mechanism might exist for the reduction of E-cadherin
expression other than that related to dysadherin expression.
When we analyzed the association between dysadherin
expression and clinicopathologic features, we could dem-
onstrate a significant association between the histologic type
of tumor and dysadherin expression. In adenocarcinomas
39.5% showed positive dysadherin expression, which was
statistically significant compared with that seen in squa-
mous cell carcinomas, of which only 28.0% showed the
same feature (P  .0442). In thyroid cancer dysadherin
Figure 3. Kaplan-Meier survival curves in relation to th
overall; B, stage I.
TABLE 3. Prognostic factors in patients with non–small c
analysis of Cox hazards model
Characteristics
Prognostic factors Unfavorable F
Dysadherin 50% 50%
E-cadherin Reduced Preserved
Lymph node metastasis Positive Negative
Differentiation Moderate/poorly Well
Histology Adenocarcinoma Squamous
Age 65 65
Sex Male FemaleCI, Confidence interval.
744 The Journal of Thoracic and Cardiovascular Surgery ● Septexpression was highest in undifferentiated carcinoma, next
highest in papillary carcinoma, and lowest in follicular
carcinoma.4 Concerning tumor differentiation, well-differ-
entiated cancer has a greater tendency toward low positive
dysadherin expression than poorly differentiated cancer,
which showed no statistically significant difference (P 
.3041).
It is interesting to note that the dysadherin expression
levels in patients with lymph node metastasis were higher
than in those without lymph node metastasis, although the
difference was not statistically significant (P  .057). On
the contrary, E-cadherin expression revealed no correlation
with lymph node metastasis (P  .3955). In a multivariate
analysis we found that the presence of lymph node metas-
tasis, dysadherin overexpression, and reduced E-cadherin
bination of E-cadherin and dysadherin expression: A,
lung carcinoma according to univariate and multivariate
ble Hazard ratio 95% CI P value
3.018 1.748-2.009 .0104
2.76 1.676-4.577 .0142
3.414 1.907-4.877 .0081
1.738 1.034-3.887 .0544
carcinoma 1.232 0.803-1.978 .3093
1.121 0.8916-2.603 .4871
0.986 0.5398-2.016 .8367e comell
avora
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TSexpression had significant independent prognostic ability. In
this series there are 74 patients with stage I lung cancers. To
eliminate the negative prognostic effects of lymph node
metastasis, we evaluated the significance of dysadherin and
E-cadherin expression restricted to patients with stage I
disease. A statistically significant difference of prognosis
could be found between the patients with positive dysad-
herin and reduced E-cadherin expression and the patients
with negative dysadherin and preserved E-cadherin expres-
sion (P  .0088). Furthermore, we intended to verify that
these factors are useful in stage IA lung cancers, but a statis-
tically significant difference could not be observed (P .109).
Only 5 patients revealed positive dysadherin and reduced
E-cadherin expression out of 44 cases.
In conclusion, dysadherin expression is an independent
prognostic factor of survival in patients with NSCLC, and
combined immunohistochemical analysis of dysadherin and
E-cadherin expression might provide further prognostic
information.
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